for the Period Ended 31 December 2021
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
As at
Notes | 2021 | 2020 | |
---|---|---|---|
| £ | £ | |
Current assets | |||
Cash at bank and in hand: | | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 3 | ( | ( |
Net current assets (liabilities): | ( | ( | |
Total assets less current liabilities: | ( | ( | |
Total net assets (liabilities): | ( | ( | |
Members' funds | |||
Profit and loss account: | ( | ( | |
Total members' funds: | ( | ( |
The notes form part of these financial statements
The directors have chosen not to file a copy of the company's profit and loss account.
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 December 2021
Basis of measurement and preparation
for the Period Ended 31 December 2021
2021 | 2020 | |
---|---|---|
Average number of employees during the period | | |
for the Period Ended 31 December 2021
2021 | 2020 | |
---|---|---|
£ | £ | |
Other creditors | | |
Total | | |
The EAASM is also involved in activities relating to patient safety in the areas of off label use of medicines and compunding of medicines and a contribution was made via a presentation to further this cause and also additional input in to theongoing programme was made to the European Brain Council who are the main coordinators of this GOLUP (Good Off Label Use Practice)The EAASM continues its major medication error and traceability patient safety project with the aim to significantly reduce medication errors by enhancing traceability processes. A scientific committee was further consulted on the generation of the comprehensive survey established along with a growing number of academic and hospital/healthcare organisations. The project has its own website and has just completed a pan EU survey across 13 countries including the private hospital association. The results have contributed to a Call to Action White Paper within the EU institutions - mainly DG Sante. A round table was held in March 22 to publicise the results of the survey and to commence the Call to Action.The EAASM is actively involved with the EU Parliament and attends relevant meetings and hosts healthcare debates in the parliament bringing together MEP's, Commission and the Council.The EAASM also supports the objectives and recommendations for the Pharmaceutical Strategy for Europe with the EU Heathcare Coalition to which it is a partner. it also contributed to the EU Commission Structural Dialogue initiative on product shortages and was an active participant in this new EU consultative approach.The EAASM recalls that the internet is the largest unregulated pharmaceutical market place in the world with 62% of medicines purchased online being falsified or substandard with 95.6% of online pharmacies researched operating illegally. The EAASM calls on the EC and the member states to build on the introduction of the common logo for online pharmacies and to extend it to a European protocol for licencing online pharmacies which could potentially align with the pre-qualifications of the .pharmacy domain suffix which is well governed by the NABP.The EAASM during 2021 continued its strong advocacy work to effect change of legislation so that nanomedicines and nanosimilars should be assessed by an EMA centralised procedure. In this regard EAASM along with the nanomedicines coalition achieved two important amendments in the EU Parliament own inititive report. A number of meetings have been held with DG Sante to raise awareness about this subject which has patient safety implications. A EU parliament round table was achieved and a new nanomedicines coalition website was launched.A July 2021 newsletter was published and is available on the EAASM website and was sent to all members on the mailing list.
No consultation with stakeholders
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
22 August 2022
And signed on behalf of the board by:
Name: Michael Isles
Status: Director